dc.contributor
Institut Català de la Salut
dc.contributor
[Guilbert TW] Department of Pediatrics, Cincinnati Children’s Hospital and University of Cincinnati, Cincinnati, OH, USA. [Tolcachier A] Center for Allergy and Respiratory Diseases, Buenos Aires, Argentina. [Fiocchi AG] Bambino Gesù Children’s Hospital IRCCS, Rome, Italy. [Katelaris CH] Department of Medicine, Campbelltown Hospital, Campbelltown, NSW, Australia. Immunology & Allergy Unit, Western Sydney University, Sydney, NSW, Australia. [Phipatanakul W] Department of Allergy and Immunology, Boston Children’s Hospital, Boston, MA, USA. Department of Pediatrics, Harvard Medical School, Boston, MA, USA. [Begin P] Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal, QC, Canada. [de Mir I] Unitat de Pneumologia Pediàtrica i Fibrosi Quística, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Guilbert, Theresa
dc.contributor.author
Tolcachier, Alberto
dc.contributor.author
Fiocchi, Alessandro
dc.contributor.author
Katelaris, Constance
dc.contributor.author
Phipatanakul, Wanda
dc.contributor.author
Begin, Philippe
dc.contributor.author
de Mir Messa, Ines
dc.date.accessioned
2025-10-24T10:39:49Z
dc.date.available
2025-10-24T10:39:49Z
dc.date.issued
2024-03-18T13:38:57Z
dc.date.issued
2024-03-18T13:38:57Z
dc.date.issued
2024-03-05
dc.identifier
Guilbert TW, Tolcachier A, Fiocchi AG, Katelaris CH, Phipatanakul W, Begin P, et al. Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study. J Asthma Allergy. 2024 Mar 5;17:143–59.
dc.identifier
https://hdl.handle.net/11351/11202
dc.identifier
10.2147/JAA.S416292
dc.identifier
001179622600001
dc.identifier.uri
https://hdl.handle.net/11351/11202
dc.description.abstract
Asthma control; Lung function; Pediatric asthma
dc.description.abstract
Control del asma; Función pulmonar; Asma pediátrica
dc.description.abstract
Control de l'asma; Funció pulmonar; Asma pediàtrica
dc.description.abstract
Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT02948959. Medical writing/editorial assistance was provided by Natalia Crespo, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines: 2022 update.
dc.format
application/pdf
dc.publisher
Dove Medical Press
dc.relation
Journal of Asthma and Allergy;17
dc.relation
https://doi.org/10.2147/JAA.S416292
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Anticossos monoclonals - Ús terapèutic
dc.subject
DISEASES::Respiratory Tract Diseases::Bronchial Diseases::Asthma
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
NAMED GROUPS::Persons::Age Groups::Child
dc.subject
ENFERMEDADES::enfermedades respiratorias::enfermedades bronquiales::asma
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.subject
DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño
dc.title
Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
